- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.10. | Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal | ||
| 22.10. | Quest Diagnostics' test results system breached in yet another medtech cyberattack | ||
| 22.10. | Rebranded NodThera plans IPO to fund NLRP3 inhibitor's push toward approval | ||
| 22.10. | Roche's CEO has 'absolutely not' changed tune on Poseida despite scrapping CAR-T from the buyout | ||
| 21.10. | 'A two-way conversation with the tumor': Researchers use 'avatar' to predict immunotherapy responses | ||
| 21.10. | Astellas links up with AI Proteins in $400M computational d rugdiscovery deal | ||
| 21.10. | Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapy | ||
| 21.10. | Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches | ||
| 21.10. | 'We're getting back to stability': CBER Director Karim Mikhail shares his strategy with Fierce | ||
| 21.10. | Biotech reverse mergers rebound to highest level since 2021 as PIPEs flood market: report | ||
| 21.10. | Advocacy organization launches data dashboard to better assess how clinical trial sites perform | ||
| 20.10. | Industry at a 'turning point' with growth dominated by commercial leaders: EY report | ||
| 20.10. | Lycia aims for $228M IPO to generate data on food allergy rival to Xolair | ||
| 20.10. | Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition | ||
| 20.10. | Hengrui has become the go-to source of China biopharma innovation. What's its secret? | ||
| 20.10. | Israeli biotech's inhaled exosome therapy reduces respiratory failure in phase 2 study | ||
| 20.10. | Pfizer makes 'business decision' to end phase 2 trial of autoimmune drug as program's future uncertain | ||
| 20.10. | AstraZeneca taps Oracle to help improve recruitment for clinical trials | ||
| 20.10. | Ambrose Healthcare inks $181M deal for former Pfizer target AM-Pharma | ||
| 19.10. | Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery | ||
| 19.10. | Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC | ||
| 19.10. | Gilead 'sitting on a foundational asset' after oral UC drug's phase 2 win | ||
| 19.10. | Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win | ||
| 19.10. | Enlivex lays off 60% of employees, scraps preclinical R&D and gives execs 'substantial' salary cuts | ||
| 19.10. | Disc spins past FDA rejection with 'overwhelmingly positive' phase 3 data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.